Results of AGM

London, 24th April 2018

Silence Therapeutics plc, AIM:SLN ('Silence' or 'the Company') a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its Annual General Meeting held on Monday, 23rd April 2018, all resolutions were duly passed.

Enquiries:

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

Tel: +44 (0)20 7418 8900

Media Enquiries:

Optimum Strategic Communications

Mary Clark/ Eva Haas/Hollie Vile

silence@optimumcomms.com

Tel: +44 (0) 20 3714 1788

IR Enquires - US

Burns McClellan

John Grimaldi

Tel: +1 (212) 213 0006

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

Attachments

  • Original document
  • Permalink

Disclaimer

Silence Therapeutics plc published this content on 24 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 24 April 2018 06:21:06 UTC